Q32 Bio Inc. (QTTB)
QTTB Stock Price Chart
Explore Q32 Bio Inc. interactive price chart. Choose custom timeframes to analyze QTTB price movements and trends.
QTTB Company Profile
Discover essential business fundamentals and corporate details for Q32 Bio Inc. (QTTB) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
28 Mar 2018
Employees
28.00
Website
https://www.q32bio.comCEO
Jodie Pope Morrison
Description
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
QTTB Financial Timeline
Browse a chronological timeline of Q32 Bio Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$1.39.
Earnings released on 6 Aug 2025
EPS came in at -$0.78 surpassing the estimated -$1.14 by +31.58%.
Earnings released on 8 May 2025
EPS came in at -$0.90 surpassing the estimated -$1.23 by +26.83%.
Earnings released on 11 Mar 2025
EPS came in at -$1.16 surpassing the estimated -$1.25 by +7.20%.
Earnings released on 7 Nov 2024
EPS came in at -$1.46 falling short of the estimated -$1.41 by -3.55%.
Earnings released on 8 Aug 2024
EPS came in at -$1.42 falling short of the estimated -$1.00 by -42.00%.
Earnings released on 9 May 2024
EPS came in at -$13.15 falling short of the estimated -$1.42 by -826.06%.
Stock split effective on 26 Mar 2024
Shares were split 1 : 18 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Mar 2024
EPS came in at -$0.28 surpassing the estimated -$0.30 by +6.67%, while revenue for the quarter reached -$14.66M , missing expectations by -3.03K%.
Earnings released on 14 Nov 2023
EPS came in at -$0.57 falling short of the estimated -$0.42 by -35.71%, while revenue for the quarter reached $1.86M , beating expectations by +271.80%.
Earnings released on 27 Jul 2023
EPS came in at -$10.98 falling short of the estimated -$8.55 by -28.42%, while revenue for the quarter reached $354.00K , missing expectations by -57.38%.
Earnings released on 30 Mar 2023
EPS came in at -$9.00 surpassing the estimated -$9.54 by +5.71%, while revenue for the quarter reached $802.00K , missing expectations by -20.95%.
Earnings released on 30 Dec 2022
EPS came in at -$10.74 falling short of the estimated -$8.86 by -21.21%, while revenue for the quarter reached $802.00K , missing expectations by -3.44%.
Earnings released on 29 Sept 2022
EPS came in at -$10.57 falling short of the estimated -$8.21 by -28.64%, while revenue for the quarter reached $802.00K , missing expectations by -6.81%.
Earnings released on 29 Jun 2022
EPS came in at -$9.12 surpassing the estimated -$9.68 by +5.70%, while revenue for the quarter reached $802.00K , missing expectations by -19.88%.
Earnings released on 30 Mar 2022
EPS came in at $28.65 , while revenue for the quarter reached $802.00K .
Earnings released on 30 Dec 2021
EPS came in at -$10.58 falling short of the estimated -$8.87 by -19.28%, while revenue for the quarter reached $802.00K , missing expectations by -88.87%.
Earnings released on 29 Sept 2021
EPS came in at -$9.65 , while revenue for the quarter reached $1.68M .
Earnings released on 29 Jun 2021
EPS came in at -$9.72 , while revenue for the quarter reached $2.19M .
Earnings released on 31 Mar 2021
EPS came in at -$0.38 , while revenue for the quarter reached $29.31M .
Earnings released on 31 Dec 2020
EPS came in at -$11.15 , while revenue for the quarter reached $980.00K .
Earnings released on 30 Sept 2020
EPS came in at -$11.24 , while revenue for the quarter reached $567.00K .
QTTB Stock Performance
Access detailed QTTB performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.